Strides flagship facility in Bangalore receives USFDA inspection closure

Strides Pharma Science Ltd (BSE: 532531, NSE: STAR, Strides or Company) announced that the U.S. Food and Drug Administration (USFDA) today issued an Establishment Inspection Report (EIR) in relation to the inspection of the Company's flagship facility in Bangalore, India.

The Company's flagship facility was inspected by the USFDA between December 5 and 9, 2022, and a form 483 listing three inspectional observations was issued. Based on the Company's response to the observations and subsequent commitments, the USFDA has classified the outcome of this inspection as VAI (voluntary action indicated), and the EIR states that the inspection is closed.

The flagship facility in Bangalore is the largest manufacturing facility for the company, with the capability to produce finished dosage formulation products across multiple dosage formats, including tablets, capsules, ointments, creams, and liquids. The facility services the key regulated markets of the US, Europe, and Australia.

Shares of Strides Pharma Science Limited was last trading in BSE at Rs. 298.80 as compared to the previous close of Rs. 298.70. The total number of shares traded during the day was 12994 in over 958 trades.

The stock hit an intraday high of Rs. 301.70 and intraday low of 296.90. The net turnover during the day was Rs. 3880645.00.

Source : Equity Bulls

Keywords

StridesPharmaScience INE939A01011 USFDA EIR BangaloreFacility India